Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2025-01-08 Earnings Release
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated January 8, 2025, announcing positive top-line results from the Phase 3 ARES pivotal study for the drug MaaT013 in treating GI-aGvHD. It details efficacy data (GI-ORR of 62%), mentions the plan to file for marketing authorization (AMM) in Europe by mid-2025, and schedules a conference call/webcast for the following day (January 9, 2025). This structure—announcing key clinical trial results and providing details about an upcoming investor call—is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since it focuses purely on clinical trial results and regulatory milestones rather than comprehensive financial performance (like a 10-K or IR), and it is an initial announcement of results (not just a link to a report), the most fitting category is Earnings Release (ER), as these often include major operational/clinical updates for biotech firms. It is not a Call Transcript (CT) as it is the announcement *before* the call, nor is it a Report Publication Announcement (RPA) because it contains the substantive news itself, not just a notice that a report is available. Q1 2025
2025-01-08 French
Inside Information / Other news releases
Earnings Release Classification · 100% confidence The document is a press release dated January 8, 2025, announcing 'Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013'. It details clinical trial outcomes (primary endpoint met, response rates, survival probability) and discusses future regulatory submissions (MAA submission in mid-2025). This content structure—announcing key financial/clinical results for a specific period or study milestone—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses specifically on clinical trial results and not comprehensive quarterly financials, it aligns best with the 'Earnings Release' definition, which covers initial announcements of periodical results (even if the period is a study phase completion rather than a fiscal quarter). It is not a full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT), although it announces a conference call. Given the focus on announcing key performance indicators (clinical efficacy data), ER is the most appropriate fit among the provided options. Q1 2025
2025-01-08 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states its purpose in the title: "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital," referencing French regulatory articles (AMF General Regulations, Commercial Code). It provides a specific table detailing the total number of shares and voting rights as of December 31, 2024. This type of mandatory periodic disclosure regarding the capital structure and voting rights does not fit neatly into the primary financial reports (10-K, IR) or standard announcements (ER, DIV). While it relates to capital structure, it is a specific regulatory disclosure about voting rights count, which is often categorized under general regulatory filings or specific capital/shareholder information. Given the options, it is a specific regulatory disclosure about the share count and voting rights, which is a form of mandatory reporting. It is not a Director's Dealing (DIRS), a Major Shareholding Notification (MRQ), or a general Dividend Notice (DIV). Since it is a specific, mandatory regulatory disclosure about the share capital structure and voting rights count, it aligns best with a general regulatory filing category, or potentially a specialized capital announcement. However, the content is purely informational regarding the total number of shares and voting rights, which is a common requirement under market regulations. Since there is no specific code for 'Voting Rights Disclosure', and it is a formal regulatory notice, 'RNS' (Regulatory Filings - general fallback) is the most appropriate fit, as it is a formal, periodic regulatory update that doesn't match the other specific codes.
2025-01-07 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of December 31, 2024. This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing, often related to capital changes or major shareholdings, but the most precise fit among the provided codes for a formal announcement detailing the total number of shares and voting rights is related to capital structure or major shareholding notifications. Since it is a formal, periodic regulatory disclosure about the capital structure (shares and voting rights), it aligns closely with notifications concerning capital changes or significant ownership structure updates. Given the options, 'SHA' (Share Issue/Capital Change) or 'MRQ' (Major Shareholding Notification) are possibilities, but the content is a direct statement of the total capital count, which is a fundamental component of capital structure reporting. However, the closest fit for a formal, periodic report on the total number of shares and voting rights, which is a regulatory requirement often linked to capital structure transparency, is often categorized under general capital updates or sometimes as a specific regulatory filing if no better fit exists. Since it explicitly details the total number of shares and voting rights, it is a direct report on the capital structure. 'SHA' covers 'Share Issue/Capital Change'. 'MRQ' covers 'Major Shareholding Notification' (changes in significant ownership levels). This document reports the *total* capital structure, not necessarily a *change* in major holdings above a threshold, nor a new share issue, but it is a mandatory disclosure about the capital base. In many regulatory contexts, this specific disclosure (total voting rights/shares) is often grouped with capital structure updates. Given the options, 'SHA' (Share Issue/Capital Change) is a reasonable classification for a document detailing the total capital base, although 'RNS' (Regulatory Filings) is a fallback. Considering the specific nature of reporting the total share count, which underpins capital structure, I will classify it as 'SHA' as it pertains directly to the capital composition, or 'RNS' if it's considered a general regulatory update. Since it is a specific, mandatory disclosure about the capital base, and not a general announcement of a report, I lean towards a specific category. Let's re-evaluate: This is a mandatory monthly disclosure of the total number of shares and voting rights, which is a key input for calculating major shareholdings (MRQ) and capital changes (SHA). Since it is a formal, periodic regulatory disclosure mandated by the AMF, and it doesn't fit perfectly into the other specific categories like DIV or ER, 'RNS' (General regulatory announcements) is the safest fit if 'SHA' or 'MRQ' are not perfectly aligned with a *monthly* total count disclosure. However, in many databases, these total share count disclosures are linked to capital structure reporting. Given the options, and recognizing this is a formal regulatory filing about the capital base, I will select 'SHA' as it relates to the fundamental capital structure being reported, although 'RNS' is also plausible. Upon review of similar filings, these monthly voting rights statements are often classified under capital structure updates. I will proceed with SHA.
2025-01-07 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from MaaT Pharma announcing positive updated data for their drug MaaT013, presented at the ASH Annual Congress 2024. It details clinical results (response rates, survival data) from a compassionate access program (EAP) and mentions upcoming Phase 3 trial results (ARES). This format—a formal announcement of clinical/scientific data updates, often coinciding with a conference presentation, and including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general scientific/clinical update. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it focuses on presenting key results rather than just announcing the publication of a report (RPA), the most fitting category is Earnings Release (ER), as these announcements often contain the most recent operational and clinical highlights intended for investors, even if the primary focus is scientific data. It is a release of key performance indicators/results. FY 2024
2024-12-10 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is a press release dated December 10th, 2024, announcing updated clinical data for MaaT013 presented at the ASH 2024 Annual Meeting. It details efficacy results (Response Rates, Overall Survival) and mentions upcoming events like a KOL webinar and the anticipation of Phase 3 topline results in January 2025. This format—a news announcement summarizing recent data presentation and future milestones—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a formal presentation (IP), the best fit among the provided options for a primary financial/operational results announcement is 'Earnings Release' (ER), as it communicates key performance indicators (clinical efficacy translating to potential commercial success) immediately following a major conference presentation. It is not a Report Publication Announcement (RPA) because it contains the substantive data itself, not just a notice that a report is available.
2024-12-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.